NAD+ 1G & TIRZEPATIDE'S SUCCESSOR : A BRITISH UPDATE

The emerging interest in NAD+ supplementation, particularly at a substantial dosage of 1g , continues to build within the UK healthcare community. At the same time , attention is focused on Retatrutide, a groundbreaking GLP-1 medication being viewed by many as a potential advancement to Tirzepati